LIR Life Sciences Corp.
BBCMF
$1.42
$0.075.54%
OTC PK
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 357.33% | 182.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 360.59% | 206.93% | |||
| Operating Income | -360.59% | -206.93% | |||
| Income Before Tax | -359.93% | -207.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -359.93% | -207.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -359.93% | -207.23% | |||
| EBIT | -360.59% | -206.93% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 98.81% | 99.19% | |||
| Normalized Basic EPS | 98.80% | 99.18% | |||
| EPS Diluted | 98.81% | 99.19% | |||
| Normalized Diluted EPS | 98.80% | 99.18% | |||
| Average Basic Shares Outstanding | 38,689.00% | 37,900.00% | |||
| Average Diluted Shares Outstanding | 38,689.00% | 37,900.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||